MFOLFOX6 plus CEDIRANIB VS MFOLFOX6 plus BEVACIZUMAB IN PREVIOUSLY UNTREATED METASTATIC COLORECTAL CANCER (MCRC): A RANDOMIZED, DOUBLE-BLIND, PHASE II/III STUDY (HORIZON III)

被引：0
|
作者：
Schmoll, H. [1 ]
Cunningham, D. [2 ]
Sobrero, A. [3 ]
Karapetis, C. [4 ]
Rougier, P. [5 ]
Koski, S. L. [6 ]
Barker, P. [7 ]
Mookerjee, B. [7 ]
Robertson, J. [8 ]
van Cutsem, E. [9 ]
机构：
[1] Univ Halle Wittenberg, Dept Internal Med 4, Halle, Germany
[2] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[3] Osped San Martino Genova, Dept Med Oncol, Genoa, Italy
[4] Flinders Med Ctr, Adelaide, SA, Australia
[5] Hop Ambroise Pare, Boulogne Billancourt, France
[6] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[7] AstraZeneca, Wilmington, DE USA
[8] AstraZeneca, Macclesfield, Cheshire, England
[9] Univ Hosp Gasthuisberg, Dept Internal Med, B-3000 Louvain, Belgium
来源：
ANNALS OF ONCOLOGY | 2010年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：189 / 189
页数：1
相关论文
共 50 条
  • [41] Phase 2 randomized controlled trial of intravenous or intraperitoneal paclitaxel plus mFOLFOX6 vs. mFOLFOX6 as first-line treatment of advanced gastric cancer
    Zhao, Shen
    Su, Liyu
    Chen, Yigui
    Li, Xiaofeng
    Lin, Peicheng
    Chen, Wujin
    Fang, Wenzheng
    Zhu, Jinfeng
    Li, Hui
    Ren, Liping
    Liu, Jie
    Hong, Yanni
    Lin, Shaowei
    Fan, Nanfeng
    Lin, Rongbo
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).
    Mise, Yoshihiro
    Hasegawa, Kiyoshi
    Oba, Masaru
    Yamaguchi, Kensei
    Uetake, Hiroyuki
    Yoshino, Takayuki
    Morita, Satoshi
    Takahashi, Keiichi
    Unno, Michiaki
    Shimada, Yasuhiro
    Muro, Kei
    Yoshida, Kazuhiro
    Mori, Masaki
    Baba, Hideo
    Shimada, Mitsuo
    Saiura, Akio
    Matsumura, Masaru
    Ishigure, Kiyoshi
    Sugihara, Kenichi
    Kokudo, Norihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [43] PRESPECIFIED SUBGROUP ANALYSES IN WJOG4407G TRIAL, A RANDOMIZED PHASE III TRIAL OF MFOLFOX6 PLUS BEVACIZUMAB VERSUS FOLFIRI PLUS BEVACIZUMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER
    Hiroshi, Tamagawa
    Kentaro, Yamazaki
    Koichi, Suyama
    Michio, Okabe
    Kazuya, Suzuki
    Nobuhiko, Seki
    Kentaro, Kawakami
    Mikio, Sato
    Yasuo, Takahashi
    Tomonori, Hirashima
    Masahide, Ebi
    Keisei, Taku
    Toshio, Otsuji
    Fumio, Tamura
    Eiji, Shinozaki
    Koji, Nakashima
    Kensei, Yamaguchi
    Masahiko, Ando
    Satoshi, Morita
    Narikazu, Boku
    Ichinosuke, Hyodo
    ANNALS OF ONCOLOGY, 2014, 25
  • [44] Efficacy and safety of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC).
    Zhou, Fuxiang
    Wang Wen-bo
    Xia, Ling
    Dai, Jing
    Wu, Han
    Yang, Lei
    Xiong, Zhiguo
    Gong, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 152 - 152
  • [45] Phase II study of mFOLFOX6 with bevacizumab (Bev) in metastatic gastric and esophageal (GE) adenocarcinoma
    Li, J.
    Kortmansky, J. S.
    Saif, M.
    Fischbach, N. A.
    Ravage-Mass, L.
    Elligers, K.
    Hahn, C.
    Cohenuram, M. K.
    Lacy, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [46] Updated results of the SOFT study: A randomized phase III trial of S-1/oxaliplatin (SOX) plus bevacizumab versus 5-FU/I-LV/oxaliplatin (mFOLFOX6) plus bevacizumab in patients with metastatic colorectal cancer (mCRC).
    Nakamura, Masato
    Yamada, Yasuhide
    Takahari, Daisuke
    Matsumoto, Hiroshi
    Baba, Hideo
    Yoshida, Kazuhiro
    Yoshida, Motoki
    Iwamoto, Shigeyoshi
    Shimada, Ken
    Komatsu, Yoshito
    Sasaki, Yasutsuna
    Satoh, Taroh
    Takahashi, Keiichi
    Mishima, Hideyuki
    Muro, Kei
    Watanabe, Masahiko
    Sakata, Yuh
    Morita, Satoshi
    Shimada, Yasuhiro
    Sugihara, Kenichi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Updated results from the multicenter phase II study of fruquintinib plus mFOLFOX6/FOLFIRI as first-line therapy in advanced metastatic colorectal cancer (mCRC)
    Zhou, F.
    Wang, W.
    Xia, L.
    Dai, J.
    Wu, H.
    Yang, L.
    Gong, J.
    Chen, X.
    Xiong, Z.
    Liang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S439 - S439
  • [48] SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6+selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [49] Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Rivera, Fernando
    Valladares, Manuel
    Gea, Salvador
    Lopez-Martinez, Noemi
    JOURNAL OF MEDICAL ECONOMICS, 2017, 20 (06) : 574 - 584
  • [50] SIRFLOX: Differences in site of first progression between mFOLFOX6 ± bevacizumab (bev) versus mFOLFOX6 ± bev plus selective internal radiation therapy (SIRT) in first-line patients (pts) with metastatic colorectal cancer (mCRC).
    Gibbs, Peter
    Heinemann, Volker
    Sharma, Navesh K.
    Findlay, Michael P. N.
    Ricke, Jens
    Peeters, Marc
    Perez, David
    Robinson, Bridget Anne
    Strickland, Andrew
    Ferguson, Tom
    Rodriguez, Javier
    Kroening, Hendrik
    Wolf, Ido
    Ganju, Vinod
    Walpole, Euan Thomas
    Boucher, Eveline
    Tichler, Thomas E.
    Gebski, Val
    Van Buskirk, Mark
    Van Hazel, Guy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345